Full-Life Technologies Acquires Focus-X Therapeutics
Full-Life Technologies, a radiotherapeutics company, has entered into an agreement to acquire Focus-X Therapeutics and its cancer-targeting radiopharmaceuticals.
Under the terms of the acquisition, Full-Life will gain Focus-X’s two investigational lead compounds. The first is a prostate specific membrane antigen-targeted peptide for the treatment of metastatic castration resistant prostate cancer. The second is a neurotensin receptor type 1 (NTSR1)-targeted peptide for the treatment of pancreatic cancer.
Full-Life will also be acquiring Focus-X’s six other programs that are in earlier stages of development.
Under the terms of the acquisition, Focus-X shareholders are eligible to receive an upfront payment along with potential development, regulatory and sales-based milestone payments of up to $245 million. The acquisition is expected to close in the first quarter of 2023.
About Full-Life Technologies Limited
Full-Life Technologies Limited is a fully integrated global radiopharmaceutical company with operations in Europe and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.
About Focus-X Therapeutics
Focus-X Therapeutics, founded in 2020, is a preclinical stage biotechnology company committed to the discovery and development of cutting-edge radiopharmaceuticals. We focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with very low five-year survival rate. We bring our proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to breakdown cancer cell DNA. As an emerging leader of RLT, our mission is to release the true potential of such modality by leveraging our world-class peptide drug discovery platform and joining force with top radiopharmaceutical partners.
November 30, 2022
